At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ACXP Acurx Pharmaceuticals, LLC*
Post-Mkt 07-01 17:03:17 EDT
1.53
-0.02
-1.29%
盘后1.51
-0.02-1.30%
16:59 EDT
High1.59
Low1.51
Vol63.12K
Open1.59
D1 Closing1.55
Amplitude5.16%
Mkt Cap6.55M
Tradable Cap6.38M
Total Shares4.28M
T/O97.18K
T/O Rate1.51%
Tradable Shares4.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Acurx says lead antibiotic ibezapolstat is ready to enter pivotal Phase 3 trials for C. difficile infection
Acurx Pharmaceuticals Announces Presentation of Results From Leiden University Medical Center Public-Private Partnership for Its DNA Pol Iiic Inhibitors at the Leiden Early Drug Discovery & Development (Led3) Scientific Conference
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.